Scarica l'app Stockscreener
95.49
6.55%
-6.695
Dopo l'orario di chiusura:
95.49
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MIRM Giù?
Forum
Previsione
Precedente Chiudi:
$102.19
Aprire:
$102.19
Volume 24 ore:
1.01M
Relative Volume:
1.04
Capitalizzazione di mercato:
$5.82B
Reddito:
$521.31M
Utile/perdita netta:
$-23.36M
Rapporto P/E:
-199.73
EPS:
-0.4781
Flusso di cassa netto:
$54.87M
1 W Prestazione:
-10.06%
1M Prestazione:
-2.51%
6M Prestazione:
+32.28%
1 anno Prestazione:
+112.15%
Intervallo 1D:
$94.31
$102.56
Intervallo di 1 settimana:
$94.31
$114.99
Portata 52W:
$42.89
$114.99
Mirum Pharmaceuticals Inc Stock (MIRM) Company Profile
Nome
Mirum Pharmaceuticals Inc
Settore
Industria
Telefono
650-667-4085
Indirizzo
989 EAST HILLSDALE BOULEVARD, SUITE 300, FOSTER CITY
Compare MIRM vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MIRM
Mirum Pharmaceuticals Inc
|
95.49 | 6.23B | 521.31M | -23.36M | 54.87M | -0.4781 |
VRTX
Vertex Pharmaceuticals Inc
|
436.58 | 110.90B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
629.68 | 73.20B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
776.26 | 49.71B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
286.27 | 38.32B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
144.37 | 30.97B | 742.00K | -1.37B | -1.07B | -7.0731 |
Mirum Pharmaceuticals Inc Stock (MIRM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-18 | Iniziato | RBC Capital Mkts | Outperform |
| 2025-09-24 | Iniziato | TD Cowen | Buy |
| 2025-08-11 | Ripresa | Stifel | Buy |
| 2025-05-19 | Ripresa | H.C. Wainwright | Buy |
| 2024-04-17 | Iniziato | Stifel | Buy |
| 2023-12-18 | Reiterato | H.C. Wainwright | Buy |
| 2023-11-20 | Ripresa | JP Morgan | Overweight |
| 2023-11-13 | Iniziato | Morgan Stanley | Overweight |
| 2023-10-24 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-10-17 | Ripresa | Evercore ISI | Outperform |
| 2023-09-20 | Iniziato | JMP Securities | Mkt Outperform |
| 2022-09-01 | Iniziato | Citigroup | Buy |
| 2021-09-20 | Iniziato | JP Morgan | Overweight |
| 2020-08-07 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2020-08-03 | Iniziato | H.C. Wainwright | Buy |
| 2020-07-31 | Iniziato | Piper Sandler | Overweight |
| 2020-06-25 | Iniziato | Robert W. Baird | Outperform |
| 2019-08-12 | Iniziato | Citigroup | Buy |
| 2019-08-12 | Iniziato | Evercore ISI | Outperform |
| 2019-08-12 | Iniziato | Guggenheim | Buy |
| 2019-08-12 | Iniziato | ROTH Capital | Buy |
| 2019-08-12 | Iniziato | Raymond James | Outperform |
Mostra tutto
Mirum Pharmaceuticals Inc Borsa (MIRM) Ultime notizie
Mirum Pharmaceuticals director Saira Ramasastry sells $218,940 stock - Investing.com
[Form 4] Mirum Pharmaceuticals, Inc. Insider Trading Activity - Stock Titan
Mirum Pharmaceuticals Issues $690 Million Convertible Senior Notes - TipRanks
Mirum Pharmaceuticals (NASDAQ: MIRM) sells $600M 2032 converts, to refinance 2029 notes - Stock Titan
Mirum Pharmaceuticals (MIRM) price target increased by 16.75% to 149.29 - MSN
Mirum Pharmaceuticals prices $600M senior notes - MSN
2,000-share sale via option exercise — MIRM (NASDAQ: MIRM) Form 144 - Stock Titan
Mirum Pharmaceuticals, Inc.common stock (NQ: MIRM - The Chronicle-Journal
Mirum's Q1 earnings & revenues beat estimates, 2026 view raised - MSN
Mirum Pharmaceuticals (MIRM) moves 5.1% higher: Will this strength last? - MSN
Latham & Watkins Advises on Mirum Pharmaceuticals’ US$600 Million Convertible Senior Notes Offering - Latham & Watkins LLP
Mirum Pharmaceuticals reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
(MIRM) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Mirum Pharmaceuticals stock (US60471A1034): Hits all-time high amid $600M debt deal - AD HOC NEWS
Mirum Pharmaceuticals stock hits all-time high at 112.47 USD By Investing.com - Investing.com Nigeria
Mirum Pharmaceuticals stock hits all-time high at 112.47 USD - Investing.com
Mirum Pharmaceuticals Prices $600 Million Private Debt Offering - Moomoo
Mirum Pharmaceuticals Prices $600.0 Million Convertible Senior Notes Offering; Refinances a Portion of 2029 Convertible Notes - BioSpace
Mirum plans $600 million convertible notes offering due 2032 By Investing.com - Investing.com South Africa
Mirum prices $600m convertible notes offering due 2032 By Investing.com - Investing.com South Africa
Mirum prices $600m convertible notes offering due 2032 - Investing.com
Mirum Pharmaceuticals Prices $600.0 Million Convertible Senior Notes Offering - TradingView
Mirum raises $600M in 0% convertible notes, starts 2029 debt swap - Stock Titan
Mirum pharmaceuticals announces proposed convertible senior notes offering - marketscreener.com
Mirum Pharmaceuticals Announces Proposed Convertible Senior Notes Offering - TradingView
Mirum Pharmaceuticals shares fall 2% after announcing $600 million bond offering - Investing.com Canada
Mirum plans $600 million convertible notes offering due 2032 - Investing.com
Mirum Pharmaceuticals Announces Private Placement of Convertible Senior Notes to Qualified Institutional Buyers - geneonline.com
User | smdailypress.comMirum Pharmaceuticals Announces Proposed Convertible Senior Notes Offering - FinancialContent
Mirum Pharmaceuticals: A Rare Disease Platform Becoming Bigger Than Its First Franchise - Seeking Alpha
Mirum Pharmaceuticals to Participate in Upcoming May 2026 Investor Conferences - BioSpace
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences - The Chronicle-Journal
Mirum Pharmaceuticals, Inc. $MIRM Shares Sold by State of New Jersey Common Pension Fund D - MarketBeat
Mirum Pharmaceuticals, Inc. (MIRM) reports Q1 loss, beats revenue estimates - MSN
Number of shareholders of Mirum Pharmaceuticals, Inc. – TRADEGATE:08D - TradingView
Nan Fung Trinity HK Ltd. Increases Stock Holdings in Mirum Pharmaceuticals, Inc. $MIRM - MarketBeat
Mirum Pharmaceuticals rally reflects confidence in late-stage liver disease assets - msn.com
MIRM Stock Clocks Best Day In 4.5 Months On Liver Disease Trial Data: Retail Eyes Buyout At A Premium - Stocktwits
Mirum Pharmaceuticals (NASDAQ:MIRM) Stock Rating Lowered by Wall Street Zen - MarketBeat
MIRM stock clocks best day in 4.5 months on liver disease trial data: Retail eyes buyout at a premium - MSN
H.C. Wainwright Maintains Mirum Pharmaceuticals(MIRM.US) With Buy Rating, Maintains Target Price $185 - Moomoo
Primary goal achieved in Mirum’s Phase IIb trial of volixibat - MSN
Mirum raises 2026 net product sales outlook to $660M-$680M as it targets year-end zilurgisertib launch - MSN
Mirum Pharmaceuticals (MIRM) Is Up 16.9% After Volixibat Phase 2b PSC Itch Data And Big Q1 LossHas The Bull Case Changed? - Yahoo Finance
RBC Capital Adjusts Mirum Pharmaceuticals Price Target to $142 From $128, Maintains Outperform Rating - Moomoo
Mirum's Q1 Earnings & Revenues Beat Estimates, 2026 View Raised - Yahoo Finance
Mirum Pharmaceuticals Inc Azioni (MIRM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.53%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):